> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Aspen Neuroscience Prices Parkinson's IPO At $15, The Bottom Of Its Range
- URL: https://www.bullished.co/aspen-neuroscience-prices-parkinsons-ipo-at-15-the-bottom-of-its-range-c9d6aea7/
- Published: 2026-10-30T02:36:18.000Z
- Updated: 2026-11-05T19:34:17.000Z
- Description: The cell-therapy developer is set to raise about $140.6 million before fees, with Nasdaq trading due to begin Friday.
- Author: Matteo Parrino
- Tags: Deals, ASPE, Industry: Healthcare, Topic: IPOs

Aspen Neuroscience, a clinical-stage biotech developing cell therapies made from a patient's own cells for Parkinson's disease, priced its initial public offering of [9,375,000 shares](https://www.globenewswire.com/news-release/2026/10/30/3391995/0/en/aspen-neuroscience-announces-pricing-of-initial-public-offering.html?ref=bullished.co) at $15.00 on Thursday, the low end of its $15-$17 marketed range. The company is set to raise about $140.6 million in gross proceeds before fees, and shares are expected to start trading on Nasdaq on Friday as ASPE.

## Priced at the floor of the range

Aspen is the only seller, so every share comes from the company rather than existing holders, the company said. The underwriters hold a 30-day option to buy up to 1,406,250 more shares at the offering price, less discounts and commissions. That option sits outside the base deal.

The shares are slated for the Nasdaq Global Select Market, and the offering is expected to close on November 2\. Leerink Partners, Piper Sandler, Stifel, UBS Investment Bank and Oppenheimer are the joint bookrunning managers.

In the IPO filing, Aspen projected a market capitalization of [$488 million](https://www.marketwatch.com/story/aspen-neuroscience-to-sell-9-4-million-shares-at-15-17-each-in-ipo-f6f653e1?ref=bullished.co) at the $16 midpoint of the range, according to MarketWatch's reading of it. The final price came in below that midpoint.

## A skin-cell therapy for Parkinson's

Aspen's lead candidate, sasineprocel, is an investigational single-dose therapy built from the patient's own cells. According to Fierce Biotech, it [converts a patient's skin cells](https://www.fiercebiotech.com/biotech/parkinsons-focused-aspen-and-bispecific-biotech-bambusa-both-shoot-134m-ipos?ref=bullished.co) into stem cells, then into neurons for implantation in the brain.

The company was founded in 2019\. Fierce reports it raised a [$70 million Series A](https://www.fiercebiotech.com/biotech/parkinsons-focused-aspen-and-bispecific-biotech-bambusa-both-shoot-134m-ipos?ref=bullished.co) by 2020, a $147.5 million Series B in 2022 and a $115 million Series C in November 2025 that included Kite Pharma.

Aspen had $72.4 million in cash at the end of June.

## Where the IPO money is going

The company's filing earmarks [about $110 million](https://www.fiercebiotech.com/biotech/parkinsons-focused-aspen-and-bispecific-biotech-bambusa-both-shoot-134m-ipos?ref=bullished.co) of proceeds for a late-stage program of sasineprocel, Fierce reports. Another roughly $8 million is set aside for its ongoing early-to-mid-stage Parkinson's trial.

ASPE is due to begin trading on Nasdaq on Friday, with the offering expected to close on Monday, November 2.

Learn

- [IPO Lockup Period Meaning: What Insiders Can Sell, When, And Where To See It →](https://www.bullished.co/learn/ipo-lockup-period-meaning/)  
An IPO lockup bars insiders from selling shares for a set period. Learn how to find the terms, what expiration means, and how insider sales are filed.

### Sources

- [Aspen Neuroscience Announces Pricing of Initial Public Offering](https://www.globenewswire.com/news-release/2026/10/30/3391995/0/en/aspen-neuroscience-announces-pricing-of-initial-public-offering.html?ref=bullished.co) — GlobeNewswire
- [Aspen Neuroscience to Sell 9.4 Million Shares at $15-$17 Each in IPO](https://www.marketwatch.com/story/aspen-neuroscience-to-sell-9-4-million-shares-at-15-17-each-in-ipo-f6f653e1?ref=bullished.co) — MarketWatch
- [Aspen Neuroscience, Inc. Form S-1/A filed October 26, 2026](https://www.sec.gov/Archives/edgar/data/2124080/000119312526431023/na-20261026.htm?ref=bullished.co) — sec.gov
- [Aspen, Bambusa both shoot for $134M IPOs](https://www.fiercebiotech.com/biotech/parkinsons-focused-aspen-and-bispecific-biotech-bambusa-both-shoot-134m-ipos?ref=bullished.co) — fiercebiotech.com
- [BedRock confirms $4.1b valuation, L Catteron's Glance, and Aspen Neuroscience's IPO](https://www.axios.com/pro/all-deals/2026/10/26/pro-rata-premium-first-look-bedrock-glance-aspen?ref=bullished.co) — Axios
- [Aspen, Bambusa target $135M IPOs; AstraZeneca vs. Takeda in gastric cancer ADCs](https://endpoints.news/aspen-bambusa-target-135m-ipos-astrazeneca-vs-takeda-in-gastric-cancer-adcs/?ref=bullished.co) — endpoints.news